Wake Forest Produce Rx Study: 8.6 mmHg SBP Reduction — How Does This Compare to First-Line Antihypertensives?

The Wake Forest 12-month produce prescription evaluation is generating significant attention — and rightfully so. An 8.6 mmHg reduction in systolic blood pressure is clinically meaningful. But the framing matters for payer conversations.

For context: first-line antihypertensive medications (ACE inhibitors, thiazide diuretics) typically produce SBP reductions of 8-12 mmHg in primary prevention populations. That means the Wake Forest produce Rx result is in the same clinical range as pharmaceutical intervention — for a fraction of the per-patient cost.

The Payer Implications

If you're making the case to a health plan medical director, the framing should be: 'Produce Rx achieves comparable SBP reduction to first-line medications, with additional benefits in food security, medication adherence, and quality of life — at a lower cost per QALY.' That's a coverage decision argument, not just a social determinants argument.

What the Study Doesn't Tell Us Yet

• Durability beyond 12 months
• Comparative effectiveness vs. combined produce Rx + MTM
• Subgroup performance by diagnosis code